Lisata Therapeutics moves forward with legal action following Kuva merger termination

Health Pharma & Biotech Written by: Angela Harmantas 08:48 Tue 04 Aug 2026 --> Proactive has a commercial relationship with Lisata Therapeutics Inc. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. She earned a Bachelor of... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Lisata Therapeutics Inc ( NASDAQ:LSTA ) View Price & Profile Lisata Therapeutics moves forward with legal action following Kuva merger termination Published: 08:48 04 Aug 2026 EDT Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to protect stockholder interests and moving swiftly to strengthen its financial position. The clinical-stage pharmaceutical company, which develops therapies for advanced solid tumors, filed the lawsuit in the Delaware Court of Chancery, alleging Kuva breached the merger agreement dated March 6, 2026. Lisata is seeking damages for the benefit of its stockholders, as well as a $2 million termination fee it says it is owed under the agreement. The company's board said it continues to actively evaluate strategic alternatives to enhance stockholder value, including a potential acquisition, merger, reverse merger, other business combination, asset sales, or liquidation and dissolution. Lisata said it will provide updates once its board approves a definitive course of action or another disclosure becomes warranted. To sharpen its focus and preserve cash for this strategic review, Lisata streamlined its workforce, reducing full-time positions by approximately 72%, including its executive vice president of research and development and chief medical officer role. The company said some affected staff may continue supporting the organization as external consultants. Lisata's lead product candidate, certepetide, is an investigational cyclic peptide designed to help co-administered or tethered anti-cancer drugs penetrate solid tumors more effectively, using the company's CendR Platform technology. Continue reading